In this study, patients receiving Eylea treatment will be treated with Yesafili, a biosimilar molecule, and routine examination results will be noted.

Start Date20 Nov 2025

Sponsor / Collaborator-

NCT04674800

/ CompletedPhase 3

A Multi Center, Extension Study to Evaluate the Safety and Efficacy of MYL-1701P in Subjects With Diabetic Macular Edema Completed MYL-1701P-3001 Study.

This Study (AFIL-IJZ-3002) is designed to evaluate the safety, efficacy and immunogenicity of MYL-1701P among a group of participants successfully completing MYL-1701P-3001 (NCT03610646) study.

Start Date23 Nov 2020

Sponsor / Collaborator

Mylan Pharmaceuticals, Inc.

[+1]

CTRI/2020/11/028961

/ CompletedPhase 3

A Multi center, Extension Study to Evaluate the Safety and Efficacy of MYL-1701P in Subjects with Diabetic Macular Edema Completed MYL-1701P-3001 Study.

Start Date03 Nov 2020

Sponsor / Collaborator

Mylan, Inc.

[+1]

100 Clinical Results associated with AFLIBERCEPT-JBVF

100 Translational Medicine associated with AFLIBERCEPT-JBVF

100 Patents (Medical) associated with AFLIBERCEPT-JBVF

Literatures (Medical) associated with AFLIBERCEPT-JBVF

04 May 2026·EXPERT OPINION ON BIOLOGICAL THERAPY

Comparability of aflibercept biosimilar with reference aflibercept in diabetic macular edema: subgroup analysis of the pivotal Phase-III INSIGHT randomized clinical trial

Article

Author: Kishino, Genichiro ; Degi, Rozsa ; Gupta, Vishali ; Barve, Abhijit ; Beckmann, Katrin ; Apte, Rajendra S. ; Ernest, Jan ; Marcus, Dennis M. ; Ganapathi, Prasanna C. ; Kamei, Motohiro ; Oleksy, Piotr ; Bose, Debdipta ; Bressler, Susan B. ; Baumane, Kristine ; Loganathan, Subramanian ; Alfaro, Daniel Virgil ; Lorenz, Katrin

BACKGROUND:

Phase-III INSIGHT study subgroup analyses observed best corrected visual acuity (BCVA) and central subfield thickness (CST) outcomes at Week 8/52 in diabetic macular edema treated with aflibercept biosimilar (MYL-1701P/Yesafili™) or reference aflibercept (Eylea®).

RESEARCH DESIGN AND METHODS:

Two mg (0.05 mL) MYL-1701P (N = 179) or reference aflibercept (N = 176) was given intravitreally every 4 weeks for 5 doses, followed by 8-weekly dosing through Week 48. Subgroups were stratified by baseline BCVA/baseline CST/age/gender/race/ethnicity/region/glycated hemoglobin (HbA1c)/anti-drug antibody status/anti-vascular endothelial growth factor therapy in fellow eye. Main outcome measures included mean change in BCVA/CST from baseline to Week 8/52 with 90% confidence interval (CI).

RESULTS:

For MYL-1701P and reference aflibercept, participants with baseline BCVA score (73-55 letters) had an adjusted mean difference of 0.03 letters in BCVA (90% CI: -1.26,1.31) and 15.46 µm in CST (90% CI: -0.02,30.93) at 8 weeks and 0.81 letters in BCVA (90% CI: -0.58,2.2) and 6.41 µm in CST (90% CI: 17.31,30.12) at 52 weeks. Subgroup categories with ≥45% participants, including CST (<400/≥400 µm) and HbA1c (<8%/>8%) had an adjusted mean difference within -3 to 3 letters (90% CI) in BCVA at 8/52 weeks.

CONCLUSIONS:

The exploratory subgroup analyses supported clinical equivalence between MYL-1701P and reference aflibercept showing clinically comparable changes in BCVA/CST across most subgroups.

TRIAL REGISTRATION:

ClinicalTrials.gov identifier is NCT03610646.

01 Apr 2026·BMJ Open Ophthalmology

Safety and efficacy of biosimilar aflibercept MYL-1701P in diabetic macular oedema: 20-week extension results following the INSIGHT pivotal trial

Article

Author: Loganathan, Subramanian ; Vohra, Rajpal ; Agarwal, Virendra ; Gupta, Vishali ; Ganapathi, Prasanna C ; Natesh, Sribhargava ; Chauhan, Rohan ; Bose, Debdipta

Aim:

To evaluate the safety, efficacy and immunogenicity of biosimilar aflibercept (MYL-1701P) in participants with diabetic macular oedema who completed the 52-week global phase III trial and were enrolled in an extension study.

Methods:

In a 20-week, multicentre, open-label extension study at 15 sites in India, safety and efficacy were assessed in 52 participants who received three doses (2 mg intravitreal) of MYL-1701P either continuing on MYL-1701P (continuation arm) or switching to it from reference aflibercept (switch arm). The primary outcome was safety, assessed by the incidence of treatment-emergent adverse events (TEAEs). The secondary outcome was efficacy and included change in visual acuity (best corrected visual acuity (BCVA) based on Early Treatment Diabetic Retinopathy Study (ETDRS) letters) and central subfield thickness ((CST); by spectral-domain optical coherence tomography).

Results:

Of the 52 participants enrolled, 46 completed week 76. Participants in both arms had comparable baseline characteristics. Incident TEAEs were noted in 9/29 participants in the continuation arm and 7/23 in the switch arm. No participant reported treatment-induced or boosted antidrug antibodies. The adjusted mean difference in BCVA change between baseline of parent study and week 76 (end of extension study) was −1.20 (2.95) ETDRS letters (90% CI −6.15 to 3.75) and from baseline of extension study to week 20 (week 76—parent study) was 1.59 (1.1) (90% CI −0.26 to 3.43). The adjusted mean difference in CST from baseline of parent study to week 76 was −15.9 (38.07) µm (90% CI −80.47 to 48.62) and from baseline of extension study to its end was 13.53 (16.13) µm (90% CI −13.86 to 40.92).

Conclusion:

The study had certain limitations, including participation from one geographical area, an open-label design and small number of participants. Despite the limited number of exposures in the switch arm, it still constituted a reasonable exposure, and similar safety, efficacy and immunogenicity profiles were observed between those who continued receiving MYL-1701P and those who switched from reference aflibercept to MYL-1701P in the 20-week extension study of the pivotal trial.

Trial registration number:

NCT04674800 , NCT03610646 .

01 Oct 2024·JAMA Ophthalmology

Aflibercept Biosimilar MYL-1701P vs Reference Aflibercept in Diabetic Macular Edema

Article

Importance:

Biosimilars may be lower-cost alternatives to originator biologic products, potentially offering expanded access or reduced economic burden, but have not been evaluated with aflibercept in diabetic macular edema (DME).

Objective:

To compare efficacy and safety of MYL-1701P, an aflibercept biosimilar, with reference aflibercept (Eylea [Regeneron]) in DME.

Design, Setting, and Participants:

This was a double-masked, randomized clinical trial that included participants at 77 centers across the US, Europe, Japan, and India. Included in the analysis were individuals 18 years and older with type 1 or type 2 diabetes with central DME and best-corrected visual acuity (BCVA) letter score of 73 to 38 in the study eye using an Early Treatment Diabetic Retinopathy Study (ETDRS) chart. Study data were analyzed from October to December 2021.

Interventions:

Formulations of MYL-1701P (0.5-mg vial) or reference aflibercept every 4 weeks for 5 consecutive intravitreal injections, followed by every 8 weeks through week 52.

Main Outcomes and Measures:

The primary outcome was the adjusted difference in least squares mean (SE) change from baseline BCVA letter score at week 8 with an equivalence margin of −3 to +3 letters. Secondary outcomes included change in central subfield thickness (CST), BCVA, number of injections over 52 weeks, incidence of adverse events (AEs), and antidrug antibodies (ADAs).

Results:

A total of 355 participants (mean [SD] age, 62.2 [9.2] years; 216 male [60.8%]) were randomized to MYL-1701P (179 participants [50.4%]) and aflibercept (176 participants [49.6%]). At week 8, mean (SE) change in BCVA was 6.60 (0.55) letters vs 6.56 (0.55) letters in the MYL-1701P vs aflibercept groups. The adjusted mean difference of 0.04 letters (90% CI, −1.16 to 1.24 letters) met the primary outcome. At week 8, mean (SE) change in CST was −112 (7) μm vs −124 (7) μm in the MYL-1701P vs aflibercept groups (adjusted mean difference, 12 μm; 90% CI, −3 to 26 μm). The incidence of treatment-emergent AEs in the MYL-1701P and aflibercept arms were ocular (30.9% [55 of 178] vs 29.5% [52 of 176]), serious ocular (0.6% [1 of 178] vs 1.1% [2 of 176]), nonocular (65.2% [116 of 178] vs 65.3% [115 of 176]), and serious nonocular (16.9% [30 of 178] vs 11.9% [21 of 176]). The mean (SD) total number of injections was 8.4 (2.1) vs 8.7 (1.8) in the MYL-1701P vs aflibercept groups. The incidence of treatment-induced or treatment-boosted ADAs was 2.8% (5 of 177) vs 5.7% (10 of 176) in the MYL-1701P vs aflibercept arms.

Conclusions and Relevance:

MYL-1701P demonstrated clinical equivalence in regard to efficacy, with comparable safety and immunogenicity, to reference aflibercept. These findings support use of MLY-1701P as an alternative to reference aflibercept.

Trial Registration:

ClinicalTrials.gov Identifier: NCT03610646

News (Medical) associated with AFLIBERCEPT-JBVF

04 Aug 2026

·retinalphysician.com

Biocon Launches Aflibercept Biosimilar Yesafili

Biocon Ltd announced in a press release the commercial launch of Yesafili (aflibercept-jbvf) in the United States. Yesafili, a vascular endothelial growth factor (VEGF) inhibitor used to treat various types of ophthalmology conditions, is a biosimilar of its reference product Eylea (aflibercept 2 mg; Regeneron). Yesafili is approved for the treatment of neovascular age-related macular degeneration, diabetic macular edema, diabetic retinopathy, and macular edema following retinal vein occulusion, making it interchangeable with Eylea for those indications. The product was approved previously and granted interchangeable designation by the US Food and Drug Administration (FDA) in May 2024. RP

Drug ApprovalFast Track

02 Aug 2026

·www.pharmaindustrial-india.com

Biocon Announces US Commercial Launch of Yesafili, a Biosimilar to Regeneron's Eylea 2 mg

Biocon has announced the commercial launch of Yesafili (aflibercept-jbvf) in the US. Yesafili, a Vascular Endothelial Growth Factor (VEGF) inhibitor used to treat various types of ophthalmology conditions, is a biosimilar of its reference product Eylea (aflibercept) 2 mg. The product was approved previously and granted interchangeable designation by the US Food and Drug Administration (FDA) in May 2024, allowing substitution at the pharmacy level in accordance with state laws. Shreehas Tambe, Chief Executive Officer (CEO) and Managing Director (MD), Biocon, said, “The launch of Yesafili in the US marks an important step in expanding the global availability of biosimilar Aflibercept 2 mg for patients with eye conditions. This milestone further strengthens our presence in ophthalmology and builds on our FDA approval as one of the first interchangeable biosimilars to Eylea 2 mg, advancing access to life-changing medicines for patients around the world.” An estimated 19.8 million Americans are living with Age-related Macular Degeneration (AMD) while US sales of aflibercept reached approximately USD 5.89 billion in 2023, underscoring the growing need for effective treatment options.

Drug ApprovalFast Track

09 Jul 2026

·www.biospace.com

Biocon Announces Publication of Pivotal Clinical Data Supporting Effectiveness of Yesafili™, a Biosimilar to Eylea® (Aflibercept)

Key findings published in the British Journal of Ophthalmology : Patients who continued on MYL‑1701P and those who switched from reference aflibercept to MYL‑1701P showed similar safety, efficacy, and immunogenicity outcomes through the 20 ‑ week extension , with maintained visual and anatomic results. Key findings published in Expert Opinion on Biological Therapy : Across clinically relevant patient subgroups, MYL‑1701P demonstrated comparable improvements in visual acuity and retinal thickness to reference aflibercept , supporting clinical equivalence across diverse DME populations. BENGALURU, India & BRIDGEWATER, N.J.--(BUSINESS WIRE)-- #Biosimilars -- Biocon Limited (BSE: 532523; NSE: BIOCON), an innovation‑led global biopharmaceutical company, today announced the publication of two important clinical studies supporting the effectiveness of Yesafili™ (aflibercept-jbvf) . The clinical data from the Phase III INSIGHT program evaluating MYL‑1701P, its aflibercept biosimilar, was published in two peer-reviewed journals, contributing to the clinical evidence base supporting the development of aflibercept MYL‑1701P for the treatment of diabetic macular edema (DME). MYL-1701P was approved and the vial format was granted interchangeable designation under the name Yesafili™ by the U.S. Food and Drug Administration in May 2024 . Shreehas Tambe, CEO & Managing Director, Biocon , said, “ Findings from these peer ‑ reviewed publications represent an important milestone for our aflibercept biosimilar program as we prepare for our upcoming launch in the United States. Together, these studies demonstrate how our science-led approach continues to expand access to biosimilars for patients. ” Safety and Efficacy of Biosimilar Aflibercept MYL‑1701P in Diabetic Macular Oedema: 20‑Week Extension Results Following the INSIGHT Pivotal Trial The first manuscript, titled “Safety and Efficacy of Biosimilar Aflibercept MYL ‑ 1701P in Diabetic Macular Oedema: 20 ‑ Week Extension Results Following the INSIGHT Pivotal Trial,” was published in the British Journal of Ophthalmology on June 29, 2026. This publication reports results from a 20‑week, multicenter, open‑label extension study enrolling participants with Diabetic Macular Edema (DME) who completed the 52‑week global Phase III INSIGHT trial. The study evaluated the safety, efficacy and immunogenicity of MYL‑1701P in participants who either continued treatment with MYL‑1701P or switched from reference aflibercept to MYL‑1701P. The results demonstrated comparable safety, efficacy, and immunogenicity profiles between participants who continued on MYL‑1701P and those who switched from reference aflibercept. Safety was assessed by the incidence of ocular and non-ocular treatment‑emergent adverse events, while efficacy outcomes included best corrected visual acuity, central subfield thickness and participants who gained ETDRS (Early Treatment Diabetic Retinopathy Study) letters. The findings demonstrate that functional and anatomic outcomes were maintained through the extension period in both treatment groups. Comparability of Aflibercept Biosimilar with Reference Aflibercept in Diabetic Macular Edema: Subgroup Analysis of the Pivotal Phase‑III INSIGHT Randomized Clinical Trial The second manuscript, titled “ Comparability of Aflibercept Biosimilar with Reference Aflibercept in Diabetic Macular Edema: Subgroup Analysis of the Pivotal Phase ‑ III INSIGHT Randomized Clinical Trial ,” was published on May 18, 2026 in Expert Opinion on Biological Therapy . This publication presents exploratory subgroup analyses from the Phase III INSIGHT randomized clinical trial comparing MYL‑1701P with reference aflibercept in participants with DME. Subgroups were defined based on baseline characteristics including visual acuity, central subfield thickness, age, gender, race, ethnicity, geographic region, glycated hemoglobin, anti‑drug antibody status, and prior anti‑VEGF therapy in the fellow eye. The subgroup analyses showed clinically comparable changes in best corrected visual acuity and central subfield thickness between MYL‑1701P and reference aflibercept across most subgroups at both early and later timepoints. The findings support clinical equivalence between the aflibercept biosimilar and reference product within the evaluated subgroups. Dr. Elena Wolff-Holz, Chief Medical Officer, Biocon , said, “ The data from these publications reinforce the clinical evidence generated through the Phase III INSIGHT trial, demonstrating consistency of outcomes following a switch from reference aflibercept and comparability across clinically relevant patient subgroups. This adds to the growing body of evidence supporting MYL ‑ 1701P as a reliable treatment option for diabetic macular edema. ” Epidemiology: There are 19.8 million Americans living with age-related macular degeneration (AMD) in the United States. 1 Macular degeneration, specifically age-related macular degeneration (AMD), is a significant health concern, especially as the population ages. It is a leading cause of irreversible vision loss in adults over 60. 2 In 2019, an estimated 12.6% of Americans age 40 and older were living with AMD, with 1.49 million (0.94%) living with vision threatening. 3 About YESAFILI (aflibercept-jbvf) The approval for YESAFILI (aflibercept-jbvf) was based on a comprehensive package of analytical, nonclinical and clinical data, which confirmed that YESAFILI is highly similar to Eylea ® . In a Phase III INSIGHT Study, YESAFILI was compared with EYLEA in patients with Diabetic Macular Edema. The study demonstrated that there were no clinically meaningful differences between YESAFILI and EYLEA in terms of pharmacokinetics, safety, efficacy, and immunogenicity. INDICATIONS AND USAGE: YESAFILI is a vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of patients with: Neovascular (Wet) Age-Related Macular Degeneration (AMD) Macular Edema Following Retinal Vein Occlusion (RVO) Diabetic Macular Edema (DME) Diabetic Retinopathy (DR) WARNINGS AND PRECAUTIONS: YESAFILI is contraindicated in patients with Ocular or periocular infection, Active intraocular inflammation and Hypersensitivity to aflibercept. Endophthalmitis, retinal detachments, and retinal vasculitis with or without occlusion may occur following intravitreal injections. Patients and/or caregivers should be instructed to report any signs and/or symptoms suggestive of endophthalmitis, retinal detachment, or retinal vasculitis without delay and should be managed appropriately. Increases in intraocular pressure have been seen within 60 minutes of an intravitreal injection. There is a potential risk of arterial thromboembolic events following intravitreal use of VEGF inhibitors. Please refer to the full Patient Information for detailed safety information. To report SUSPECTED ADVERSE REACTIONS, contact Biocon at 1-833-986-1468. About Biocon Limited Biocon Limited (BSE: 532523, NSE: BIOCON) is a global biopharmaceutical company driven by its purpose to provide affordable, life-changing medicines to patients worldwide. Headquartered in Bengaluru, India, Biocon addresses some of the world’s most pressing healthcare challenges across chronic and non-communicable diseases by offering both biosimilars and generics at scale across geographies. Through this diversified portfolio, Biocon focuses on areas of high unmet need, spanning key therapy areas including diabetes, oncology, obesity, cardiovascular diseases, immunology, ophthalmology, and bone health. The Company has pioneered several industry firsts that have helped shape the global biosimilars landscape. To date, the company has commercialized 12 biosimilar products and 30+ generic formulations globally. It has robust research and development pipeline of 20+ biosimilar assets, as well as GLP-1 peptides and other complex generics. With an integrated lab-to-patient model, Biocon brings together research and development, manufacturing, and commercial capabilities to ensure reliable and scalable supply of medicines. The company operates in more than 120 countries, supported by seven manufacturing sites, three R&D sites, 18 offices worldwide, and a workforce of over 9,500 employees. Biocon has been included in the S&P Global Sustainability Yearbook 2026 for the fourth consecutive year, underscoring its commitment to sustainable and responsible growth. Website: Follow us on X: @bioconlimited LinkedIn: Biocon Forward-Looking Statements: Biocon This press release may include statements of future expectations and other forward-looking statements based on management’s current expectations and beliefs concerning future developments and their potential effects upon Biocon and its subsidiaries/ associates. These forward-looking statements involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. Important factors that could cause actual results to differ materially from our expectations include, amongst other: general economic and business conditions in India and overseas, our ability to successfully implement our strategy, our research and development efforts, our growth and expansion plans and technological changes, changes in the value of the Rupee and other currency changes, changes in the Indian and international interest rates, change in laws and regulations that apply to the Indian and global biotechnology and pharmaceuticals industries, increasing competition in and the conditions of the Indian and global biotechnology and pharmaceuticals industries, changes in political conditions in India and changes in the foreign exchange control regulations in India. Neither Biocon, nor our Directors, or any of our subsidiaries/associates assume any obligation to update any particular forward-looking statement contained in this release. YESAFILI is a trademark of Biocon Biologics Limited. BIOCON BIOLOGICS is a registered trademark of Biocon Biologics Limited. BIOCON and the Biocon Logo are registered trademarks of Biocon Limited. All other trademarks, registered or unregistered, are the property of their respective owners. 1 Prevalence of Age-Related Macular Degeneration in the US in 2019 | Geriatrics | JAMA Ophthalmology | JAMA Network 2 Macular Degeneration: Symptoms, Diagnosis & Treatment 3 VEHSS Modeled Estimates: Age-Related Macular Degeneration (AMD) | Vision and Eye Health Surveillance System (VEHSS) | CDC Contacts For More Information: Biocon MEDIA Rumman Ahmed Senior Director – Biocon +91-9845104173 rumman.ahmed@biocon.com Lance Longwell Public Relations Lead – Advanced Markets, Biocon +1 857 270 4391 lance.longwell@biocon.com INVESTORS Prashant Nair Head of Investor Relations – Biocon +91-9820095476 prashant.nair@biocon.com

100 Deals associated with AFLIBERCEPT-JBVF

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	L01XX44 S01LA05	-

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Vision, Low	Canada	Biocon Biologics Ltd. (India)	27 Jun 2025
Diabetic Retinopathy	United States	Biocon Biologics, Inc.	20 May 2024
Diabetic macular oedema	European Union	Biocon Biologics Ireland Ltd.	15 Sep 2023
Diabetic macular oedema	Iceland	Biocon Biologics Ireland Ltd.	15 Sep 2023
Diabetic macular oedema	Liechtenstein	Biocon Biologics Ireland Ltd.	15 Sep 2023
Diabetic macular oedema	Norway	Biocon Biologics Ireland Ltd.	15 Sep 2023
Myopic choroidal neovascularization	European Union	Biocon Biologics Ireland Ltd.	15 Sep 2023
Myopic choroidal neovascularization	Iceland	Biocon Biologics Ireland Ltd.	15 Sep 2023
Myopic choroidal neovascularization	Liechtenstein	Biocon Biologics Ireland Ltd.	15 Sep 2023
Myopic choroidal neovascularization	Norway	Biocon Biologics Ireland Ltd.	15 Sep 2023
Retinal vein occlusion-related macular edema	European Union	Biocon Biologics Ireland Ltd.	15 Sep 2023
Retinal vein occlusion-related macular edema	Iceland	Biocon Biologics Ireland Ltd.	15 Sep 2023
Retinal vein occlusion-related macular edema	Liechtenstein	Biocon Biologics Ireland Ltd.	15 Sep 2023
Retinal vein occlusion-related macular edema	Norway	Biocon Biologics Ireland Ltd.	15 Sep 2023
Wet age-related macular degeneration	European Union	Biocon Biologics Ireland Ltd.	15 Sep 2023
Wet age-related macular degeneration	Iceland	Biocon Biologics Ireland Ltd.	15 Sep 2023
Wet age-related macular degeneration	Liechtenstein	Biocon Biologics Ireland Ltd.	15 Sep 2023
Wet age-related macular degeneration	Norway	Biocon Biologics Ireland Ltd.	15 Sep 2023

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04674800 (CTgov)	Phase 3	Diabetic macular oedema	52	MYL-1701P, a proposed biosimilar to Eylea	nwprnpnexv = avssoqddac sppntkvnow (bruqfsgkkd, ybwfeqdkxh - yzpteztmcb) View more	-	03 Aug 2026
NCT03610646 (INSIGHT, Pubmed \| Expert Opin Biol Ther)	Phase 3	Diabetic macular oedema	355	aflibercept biosimilar (MYL-1701P/Yesafili)	efbuclpmxh(kyrlcdxihi): Difference (Mean) = 0.81 (90.0% CI, -0.58 to 2.2) View more	Positive	04 May 2026
				reference aflibercept (Eylea)
NCT03610646 (not provided, Pubmed \| JAMA Ophthalmol)	Phase 3	Diabetic macular oedema	355	MYL-1701P	dbwsidtnym(zdqeegrdpb) = rmqmfjzrdu lfmtlvahak (elmoezknwv, 0.55) View more	Positive	12 Sep 2024
				Aflibercept	dbwsidtnym(zdqeegrdpb) = cticslndpb lfmtlvahak (elmoezknwv, 0.55) View more
FDA_CDER Manual	Not Applicable	Diabetic Retinopathy	297	Aflibercept 2 mg Q8 weeks	nclwposxvf(nwkfjzhmvx) = kvodijtwhe dfanjwwkaj (cdzukzrbzl )	Positive	20 May 2024
				Aflibercept 2 mg Q4 weeks	nclwposxvf(nwkfjzhmvx) = yhuktxbqry dfanjwwkaj (cdzukzrbzl )
FDA_CDER Manual	Phase 3	Wet age-related macular degeneration	905	Aflibercept 2 mg Q8 weeks	emrfvuhlne(uunbpesnxr) = oqjuielzte wvwhbokvuz (iqadsijzvp ) View more	Positive	20 May 2024
				Aflibercept 2 mg Q4 weeks	emrfvuhlne(uunbpesnxr) = awcylrumog wvwhbokvuz (iqadsijzvp ) View more
FDA_CDER Manual	Phase 3	Retinal vein occlusion-related macular edema	181	Aflibercept 2 mg Q4 weeks	zsnpbzkvtz(ljtwlrkmdy) = jqkcwikezw niuvwhfotx (aprixuqdsq ) View more	Superior	20 May 2024
FDA_CDER Manual	Phase 3	Diabetic macular oedema	459	Aflibercept 2 mg Q8	jsiazazgay(zczzwzcqtq) = bxurjembha souwjxcurv (fcfceoqwir, 8.2) View more	Positive	20 May 2024
				Aflibercept 2 mg Q4 weeks	jsiazazgay(zczzwzcqtq) = bvsfyoscjy souwjxcurv (fcfceoqwir, 9.5) View more
FDA_CDER Manual	Phase 3	Retinal vein occlusion-related macular edema	187	Aflibercept 2 mg Q4 weeks	kemvwfxgjn(hpbubwfyyx) = eootxhlnfj xejrujnpit (ezzcvklxrv ) View more	Superior	20 May 2024
FDA_CDER Manual	Phase 3	Diabetic macular oedema	403	Aflibercept 2 mg Q8 weeks	zbuqvejqnv(xwbzbqsuzo) = jyabihyapu zafprrbgxt (lobcynjtqd, 9.3) View more	Positive	20 May 2024
				Aflibercept 2 mg Q4 weeks	zbuqvejqnv(xwbzbqsuzo) = rcyfzaslrf zafprrbgxt (lobcynjtqd, 9.6) View more
FDA_CDER Manual	Not Applicable	Diabetic Retinopathy	451	Aflibercept 2 mg Q8 weeks	uygullkydh(nejlhbqwvw) = xcsripdxgv jkudxcwftc (fvnlnwpsen )	Positive	20 May 2024
				Aflibercept 2 mg Q4 weeks	uygullkydh(nejlhbqwvw) = khofuwmqvh jkudxcwftc (fvnlnwpsen )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis